Table 3.
Prognostic Factor Analysis for the Detection of Clinically Significant (CS, defined as Gleason Score (GS) ≥ 3+4=7) and Total Prostate Cancer (PCa) Detection on Systematic and Fusion Biopsy (SBx and FBx, respectively).
| Systematic Bx | Targeted Bx | |||||||
|---|---|---|---|---|---|---|---|---|
| Detection of Clinically Significant Cancer | Detection of All Cancers | Detection of Clinically Significant Cancer | Detection of All Cancers | |||||
| Odds Ratio (95% CI) | P-value | Odds Ratio (95% CI) | P-value | Odds Ratio (95% CI) | P-value | Odds Ratio (95% CI) | P-value | |
| Age | 1.11 (1.07–1.15) |
<0.001 | 1.07 (1.04–1.10) |
<0.001 | 1.09 (1.06–1.13) |
<0.001 | 1.07 (1.04–1.12) |
<0.001 |
| Race | ||||||||
| African American | 1.83 (1.03–3.36) |
0.044 | 2.21 (1.35–3.61) |
0.002 | 1.06 (0.57–2.00) |
0.849 | 1.38 (0.80–2.37) |
0.242 |
| Other | 1.16 (0.50–2.72) |
0.753 | 1.37 (0.70–2.73) |
0.359 | 0.88 (0.37–2.11) |
0.771 | 0.88 (0.41–1.87) |
0.736 |
| PSA | 1.03 (1.01–1.05) |
0.001 | 1.04 (1.02–1.06) |
<0.001 | 1.09 (1.06–1.12) |
<0.001 | 1.07 (1.04–1.10) |
<0.001 |
| Prostate Volume | 0.98 (0.98–0.99) |
<0.001 | 0.99 (0.98–0.99) |
<0.001 | 0.96 (0.95–0.97) |
<0.001 | 0.97 (0.96–0.98) |
<0.001 |
| Abnormal DRE | 1.24 (0.45–3.41) |
0.675 | 1.07 (0.44–2.60) |
0.882 | 1.06 (0.35–3.22) |
0.922 | 0.94 (0.35–2.55) |
0.908 |
| Positive Family History | 1.54 (0.94–2.54) |
0.087 | 1.71 (1.14–2.57) |
0.009 | 1.42 (0.87–2.33) |
0.164 | 1.68 (1.09–2.58) |
0.019 |
| Prior Negative Biopsy | 0.76 (0.63–0.92) |
0.006 | 0.75 (0.64–0.88) |
<0.001 | 0.86 (0.69–1.06) |
0.151 | 0.87 (0.72–1.04) |
0.126 |
| MRI Suspicion Score | 1.72 (1.34–2.21) |
<0.001 | 1.40 (1.15–1.70) |
0.001 | 2.26 (1.77–2.91) |
<0.001 | 1.82 (1.47–2.25) |
<0.001 |